Skip to main content
v2026.11,986 entries · CC-BY 4.0

ICH M4Q: What the CTD Quality Revision M4Q(R2) Changes and Its Status

ICH M4Q(R2) reorganises CTD Module 2.3 and 3 by material and lifecycle. Structure changes, the draft’s status and the work plan timeline, dated Nov 2026.

Written and maintained by CASRAI Editorial Board

Published

On this page

ICH M4Q is the quality part of the Common Technical Document (CTD), the harmonised format in which pharmaceutical quality information is organised for registration applications; M4Q(R2) is its first major revision, which reorganises Module 2.3 and Module 3 around materials and lifecycle management rather than the older drug substance and drug product headings. As of 17 November 2026 M4Q(R2) is a draft at ICH Step 2: it was endorsed on 14 May 2025, its public consultation has closed, and FDA lists it as draft guidance that is not for implementation. Applications continue to follow the current M4Q(R1) structure until regulators announce otherwise.

What ICH M4Q is and who runs it

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) develops the CTD guidelines. The M4 family covers the organisation of the CTD, and M4Q is the quality component: it fixes where chemistry, manufacturing and controls (CMC) information sits in an application. The background concept is covered in the ICH M4 Common Technical Document term, and the electronic wrapper is described under eCTD.

The M4Q(R2) work is led by an ICH Expert Working Group. Its work plan dated 10 July 2026 names Dr Lawrence Yu (FDA) as rapporteur and Dr Hugo Hamel (Health Canada) as regulatory chair, and records that the proposal was endorsed in May 2020 and the Step 2a draft in May 2025. FDA hosts the draft text and runs its own comment docket for it (FDA-2025-D-2275, CDER and CBER).

Scope: what M4Q(R2) covers

The draft states that it establishes the location and structure of quality information for registration applications of all medicinal products for human use. It applies to initial marketing applications and to post-approval submissions, and it supports master files. Sections that do not apply to a product are left out, and the examples in the text are illustrative rather than requirements.

FDA describes the purpose as improving the efficiency of registration and lifecycle management, supporting digitalisation and knowledge management, and providing for emerging technologies. The draft text itself names advanced manufacturing, structured data management, artificial intelligence and machine learning, and bioinformatics among the emerging concepts that more granular sections are meant to accommodate. A stated aim is a single M4Q(R2) dossier that can be used across regions; region-specific information goes in the relevant section only where it is legally unavoidable.

What M4Q(R2) changes: the new structure

Three layers instead of two

Under M4Q(R2) the quality information is organised across three layers that are written to be complementary:

  • Module 2.3.3 Core Quality Information (CQI): the core quality content for each material.
  • Module 2.3.4 Development Summary and Justification (DSJ): the development story and the justification for the choices made.
  • Module 3.2 Body of Data: the repository for detailed descriptions of methods, data and other quality information that supports Module 2.3.

The draft describes Module 2.3 as the basis for regulatory assessment and lifecycle management, and Module 3 as the supporting repository. It also states that Module 2.3 does not supersede regional post-approval change requirements. Module 2.3 additionally carries 2.3.1 General Information, 2.3.2 Overall Development and Overall Control Strategy (including the quality target product profile and a representation of the overall control strategy), 2.3.5 Product Lifecycle Management, and an optional 2.3.6 Product Quality Benefit Risk.

Material-based organisation

The most visible change is in the headings. In M4Q(R2) the sections are organised by material, using two-letter codes such as DS for drug substances and DP for drug products, and each material section is built from the same four elements: Description, Manufacture, Control and Storage. Analytical Procedures (AP) and Facilities (FA) use different headers. Section headers can carry keywords: those in parentheses are mandatory and those in square brackets are optional. The Module 3 body of data in the draft uses headings such as 3.2.DS and 3.2.DP and does not use the 3.2.S and 3.2.P lettering that readers of M4Q(R1) are used to. For a walk through of the current tree, see the CASRAI guide to eCTD Module 3 quality information.

The data table below lists the material codes in the draft, their names, and in which of the three layers each code has a section heading in the draft’s table of contents.

Product lifecycle management in Module 2.3.5

Section 2.3.5 turns lifecycle management into a defined part of the dossier. It has a change summary and justification (2.3.5.1), a Product Lifecycle Management (PLCM) document (2.3.5.2) and a place for post-approval change management protocol (PACMP) content (2.3.5.3). The PLCM document follows ICH Q12 and can include Established Conditions (ECs), reporting categories for changes to ECs, PACMPs and post-approval CMC commitments. The draft is explicit that identifying ECs in the core quality information is not mandatory unless a regional requirement says so, that ECs can be listed in tabular form or by unambiguous reference, and that stating reporting categories is optional, with regional guidelines applying otherwise. Post-approval quality commitments are to be listed in a table and updated over the product lifecycle. A change summary gives the nature of the change, a table comparing present and proposed content with the CTD sections updated, and the justification.

The draft ties its development summary to other ICH guidelines rather than restating them. For example, the analytical procedure development section (2.3.4.AP.3) refers to ICH Q14, and the lifecycle section builds on ICH Q12. The table below sets out how these related guidelines relate to the revision.

Guideline Connection to M4Q(R2) in the draft CASRAI page
ICH Q12 Source of the PLCM document, Established Conditions and PACMP concepts used in 2.3.5 —
ICH Q14 Referred to by 2.3.4.AP.3 Analytical Procedure Development ICH Q14 guide
ICH Q2(R2) Companion guideline on validation of analytical procedures; the draft holds analytical procedures in its AP sections ICH Q2(R2) guide

Eligibility and who it applies to

There is no eligibility test: M4Q(R2) is a content and structure standard for applicants, not a programme with entry criteria. When adopted it is intended to apply to the quality section of registration applications for all medicinal products for human use. Whether, how and when it is applied in a given region depends on that regulator’s implementation. For now FDA states that the guidance is a draft, not for implementation, and accepts comments at any time under 21 CFR 10.115(g)(5). FDA has noted that its copy of the draft is left in ICH format and that a final version will be reformatted.

How to prepare while it is a draft

The steps below are preparation, not compliance requirements, because the text can still change.

  1. Keep submitting in the current structure. Nothing in the draft changes what applicants must file today.
  2. Map your current content. ICH published a mapping of M4Q(R1) to M4Q(R2) in December 2025 and a mock example in November 2025, according to its work plan; they show where existing 3.2.S and 3.2.P content would land.
  3. Identify the information that becomes Core Quality Information. Decide which statements are the core content for each material and which belong in the development summary or the body of data.
  4. Review lifecycle assets. If you maintain Established Conditions, comparability protocols or post-approval commitments, note where 2.3.5 would hold them.
  5. Follow regional announcements. Comment through the regulator’s docket where one is open, and watch the regional implementation notices after adoption.

Typical timeline phases

ICH guidelines move through numbered steps: a draft is endorsed (Step 2), consulted on by the regions, revised after consultation, then signed off (Step 3) and adopted (Step 4), after which each region implements it. The M4Q(R2) work plan dated 10 July 2026 shows the following phases, with future items described as anticipated in that plan and subject to change.

Phase What the work plan records
Proposal New topic endorsed May 2020
Draft endorsement (Step 2a) Endorsed May 2025
Supporting material Mock example November 2025; mapping of M4Q(R1) to M4Q(R2) December 2025; Q&A deliverable April 2026
Public consultation Completed March 2026, with over 2,500 comments
Revision after consultation June 2026: the working group agreed proposed revisions to 2.3.1, 2.3.2, 2.3.3, 2.3.5 and 2.3.6; review and resolution of public comments anticipated November 2026
Sign-off and adoption Step 3 sign-off and Step 4 adoption anticipated June 2027

The same plan lists a face-to-face working group meeting in Prague in December 2026, including a proposal from the Implementation Working Group. Implementation timing is set by each regulator after Step 4.

Common mistakes

  • Treating the draft as in force. FDA marks it not for implementation; submissions still follow the current structure.
  • Looking for 3.2.S and 3.2.P in the new text. M4Q(R2) uses material codes, so a direct heading-for-heading match to M4Q(R1) does not exist; use the ICH mapping instead.
  • Assuming Established Conditions are now compulsory. The draft says identifying them in the core quality information is not mandatory unless a regional requirement says so.
  • Treating Module 2.3 as a copy of Module 3. The draft assigns the summary layers and the body of data different jobs, and says Module 2.3 does not supersede regional post-approval change requirements.
  • Quoting a final date as fact. Step 4 timing is only anticipated in the work plan.

Sources

Data: ICH M4Q(R2) draft: material codes and the CTD layers where each has a section

Compiled from the table of contents of the ICH M4Q(R2) Step 2 draft (hosted by FDA): each material code with its name and whether the draft has a section for it in Module 2.3.3 Core Quality Information, Module 2.3.4 Development Summary and Justification and Module 3.2 Body of Data.

Period covered: 2025/2026.

ICH M4Q(R2) draft: material codes and the CTD layers where each has a section
Material code and nameIn 2.3.3 CQIIn 2.3.4 DSJIn 3.2 Body of Data
DS Drug SubstancesYesYesYes
SI Substance IntermediatesYesNoYes
SM Starting/Source MaterialsYesYesYes
RM Raw MaterialsYesNoYes
EX ExcipientsYesNoYes
RS Reference Standards and/or MaterialsYesYesYes
IM ImpuritiesNoNoYes
DP Drug ProductsYesYesYes
PI Product IntermediatesYesNoYes
MD Medical DevicesYesYesYes
PM Packaged Medicinal Products (multiconstituent products)YesYesYes
PH Pharmaceutical Product after transformationYesYesYes
AP Analytical ProceduresYesYesYes
FA FacilitiesYesNoYes

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about ICH M4Q: What the CTD Quality Revision M4Q(R2) Changes and Its Status

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →